March 05, 2018
1 min read

Clearside announces CLS-TA achieves endpoints in phase 3 PEACHTREE trial

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Clearside Biomedical released positive topline results from a pivotal phase 3 clinical trial of suprachoroidal CLS-TA for patients with macular edema associated with noninfectious uveitis.

The randomized, masked, sham-controlled PEACHTREE trial included 160 patients, of which 96 were randomized to the treatment arm and received two 4 mg doses of suprachoroidal CLS-TA 12 weeks apart. The other 64 patients were randomized to undergo sham procedures at the same 12-week interval, according to a company press release.

Suprachoroidal CLS-TA is a proprietary suspension of triamcinolone acetonide that is administered to the back of the eye via the suprachoroidal space.

Patients in both arms were evaluated every 4 weeks for 24 weeks; 155 patients completed the entire evaluation period.

Forty-seven percent of patients who received suprachoroidal CLS-TA gained at least 15 letters in best corrected visual acuity from baseline to week 24 (P < .001), the primary endpoint of the study, compared with 16% of patients who underwent the sham procedure.

The mean improvement for the treatment arm was 9.6 letters gained at week 4 and 13.7 letters at week 24 compared with 1.2 letters at week 4 and 2.9 letters at week 24 in the control arm.

For the secondary endpoint, suprachoroidal CLS-TA resulted in a mean reduction of 157 µm in central subfield thickness from baseline at week 24 compared with a 19 µm mean reduction in the control arm (P < .001).

No treatment-related serious adverse events were reported in the suprachoroidal CLS-TA arm.

The company expects to submit an FDA new drug application for suprachoroidal CLS-TA for macular edema associated with uveitis in the fourth quarter.